DoxorubicinAntibiotics, AntineoplasticInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantTaxoidsCombined Modality TherapyAntineoplastic AgentsBreast NeoplasmsCisplatinTreatment OutcomeCell Line, TumorDisease-Free SurvivalDrug Resistance, NeoplasmRadiotherapy, AdjuvantCyclophosphamideNeoplasm StagingRemission InductionSurvival AnalysisFluorouracilPaclitaxelApoptosisCaspase 12Survival RateDrug Administration ScheduleTumor Suppressor Protein p53Adjuvants, ImmunologicNeoadjuvant TherapyNeoplasm Recurrence, LocalPrognosisLung NeoplasmsEtoposideVincristineCarcinoma, Squamous CellHead and Neck NeoplasmsCarboplatinAntineoplastic Agents, PhytogenicNeoplasm MetastasisCardiomyopathiesMethotrexateAdjuvants, PharmaceuticTumor Markers, BiologicalAdenocarcinomaDeoxycytidineDaunorubicinCarcinoma, Non-Small-Cell LungCytarabineFollow-Up StudiesLymphatic MetastasisTime FactorsVinblastineMitochondria, HeartIfosfamideDNA DamageKaplan-Meier EstimateLeukemia, Myeloid, AcuteTamoxifenDose-Response Relationship, DrugGene Expression Regulation, NeoplasticNeutropeniaAnthracyclinesRNA, MessengerSignal TransductionMyocardiumRNA, Small InterferingHeartAntineoplastic Agents, HormonalRadiotherapyEpirubicinAntimetabolites, AntineoplasticLeucovorinRetrospective StudiesInfusions, IntravenousTumor BurdenProspective StudiesRadiotherapy DosageFreund's AdjuvantBleomycinBone NeoplasmsOrganoplatinum CompoundsGranulocyte Colony-Stimulating FactorColonic NeoplasmsClinical Trials as TopicEnzyme InductionNeoplasmsChemoradiotherapyMitoxantroneRandomized Controlled Trials as TopicLevamisolePrecursor Cell Lymphoblastic Leukemia-LymphomaBrain NeoplasmsAntibodies, Monoclonal, HumanizedDisease ProgressionSalvage TherapyAntibodies, MonoclonalTesticular NeoplasmsIdarubicinHypopharyngeal NeoplasmsTumor Necrosis Factor-alphaOvarian Neoplasms